Newsletter | April 22, 2021

04.22.21 -- Interacting With FDA During Biosimilar Development

Featured Editorial
Industry Insights
Is Your Biologics At Risk For Protein Aggregation? Part 2

The manufacture of sterile injectables is fraught with risk, especially when it comes to protein aggregation in biologics drugs. We offer steps you can take to help prevent aggregation.

Approaches To Improve Efficiency In Biopharmaceutical Process Development

Time-to-experiment, time-to-clinic, and time-to-market are becoming even more important for developers and manufacturers of biopharmaceuticals. These tools make process development more efficient.

Integrated Systems For Sophisticated Drug Device Combination Products

In this interview, experts discuss the benefits of using integrated systems for sophisticated drug device combination products with multiple device subsystems and the crucial role that BD can play as a systems integrator, delivering manifold advantages to its clients.

News Headlines
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.